CC
DNLI icon

Corton Capital’s Denali Therapeutics DNLI Stock Holding History

Corton Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,578
Closed -$224K – 447
2023
Q2 		$224K Buy
+7,578
New +$213K 0.11% 296
2022
Q4 		– Sell
-14,154
Closed -$434K – 328
2022
Q3 		$434K Sell
14,154
-1,819
-11% -$59.1K 0.53% 53
2022
Q2 		$470K Buy
+15,973
New +$418K 0.44% 63

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Corton Capital's DNLI Position: Q3 2023 in Review

Corton Capital sold out of Denali Therapeutics (DNLI) in Q3 2023, closing a stake of 7,578 shares — an estimated $224K sold.

Corton Capital first reported a position in DNLI in Q2 2022 and held it in 3 quarters. The position peaked at $470K in Q2 2022. 194 funds tracked by Wall St. Rank hold DNLI as of Q3 2023.

  • Corton Capital reported no remaining Denali Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Corton Capital sold 7,578 Denali Therapeutics shares in Q3 2023, an estimated $224K.
  • Corton Capital first reported a position in Denali Therapeutics in Q2 2022 and held it in 3 quarters.
  • Corton Capital's Denali Therapeutics position peaked at $470K in Q2 2022.
  • 194 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2023.

Based on Corton Capital's 13F filing for Q3 2023, filed 14 Nov 2023.